Serostatus Split Reveals Two Genetic Patterns in Atrophic Gastritis
A large genome-wide association meta-analysis has separated atrophic gastritis into two genetically distinct clinical patterns depending on anti-H. pylori IgG serostatus. In practice, the finding matters because atrophic gastritis is not only a precursor to gastric cancer but also a cause of iron-deficiency anemia, vitamin B12 deficiency, and pernicious anemia. The study examined 214,747 Japanese participants across discovery and replication phases, then extended the analysis with cross-ancestry chronic gastritis data from FinnGen, UK Biobank, and the Million Veteran Program. The scale alone gives the results unusual weight for a disease that has often been studied in smaller cohorts where genetic heterogeneity could not be resolved.
One signal is hard to miss: seropositive disease and seronegative disease did not behave the same way. Seropositive atrophic gastritis and severe atrophic gastritis aligned more closely with loci already tied to gastric cancer, while seronegative cases showed stronger relationships with immune-related regions, particularly the MHC class II locus. That split suggests two biological routes into the same end-stage gastric phenotype, one shaped by epithelial and mucus-barrier injury in the setting of prior or current H. pylori exposure, the other driven by host immune architecture even in the absence of measurable serologic evidence of infection.
Genome-Wide Signals Point to Barrier Injury and Immune Susceptibility
Across six Japanese genome-wide association meta-analyses, investigators identified genome-wide significant associations in 17 genomic regions. Among the strongest signals in seropositive AG/SAG were PSCA and MUC1/MTX1, both previously reported gastric cancer susceptibility loci. The same regions were replicated at genome-wide significance, strengthening the argument that atrophic change and malignant transformation share a genetic scaffold rather than representing unrelated outcomes along a clinical timeline.
The MUC1/MTX1 result deserves special attention. MUC1 is a mucin gene, and mucins are central to the gastric epithelial barrier. A positive genotype-by-serostatus interaction at MUC1/MTX1 in severe atrophic gastritis suggests that the effect of this locus depends on whether a person is seropositive for H. pylori. In biological terms, a compromised mucus layer can make the stomach lining more vulnerable to chronic inflammatory damage, and repeated injury can gradually remodel the mucosa toward atrophy and dysplasia. The genetic signal fits that pathophysiology cleanly.
Seronegative disease pointed elsewhere. The MHC class II region carried predominant associations in seronegative atrophic gastritis and severe atrophic gastritis, with specific HLA class II alleles including HLA-DRB115:01 and HLA-DQB106:02 implicated in that group. FAP, CCR6, and ATP4A also emerged for seronegative severe atrophic gastritis. These loci map onto immune presentation, inflammatory trafficking, and gastric acid biology, consistent with a phenotype that may be less dependent on classic serologic evidence of H. pylori but still rooted in host-mediated gastric injury.
Shared Genetic Architecture with Gastric Cancer Is Not Subtle
The most clinically important result is the overlap with gastric cancer. The study reports a linkage between atrophic gastritis and cancer that is not merely conceptual; it is genetically measurable. The linkage disequilibrium score regression genetic correlation between AG and GC was 0.529, and the MTAG estimated Omega correlation was 0.694. Those values point to substantial shared heritability rather than a loose epidemiologic association.
Local genetic correlation analysis and structural equation modeling reinforced the same direction of travel. The gastric mucosa appears to move along a continuum in which inherited susceptibility influences how effectively the tissue withstands chronic inflammation, how rapidly atrophy develops, and how likely it is to progress toward neoplasia. The inflammatory trigger may be microbial in some patients and more immune-patterned in others, but the downstream consequence is similar: epithelial disruption, gland loss, and a biologic environment favorable to malignant evolution.
Two additional findings sharpen that interpretation. ABO and PRKAA1/PTGER4 fell within previously reported gastric cancer susceptibility regions, while additional candidate loci such as BMP2, CCDC80, LRRC34, CPEB4, PGC/FRS3, and LMTK2 implicated epithelial regulation, immune responses, transcriptional control, and differentiation. These are not random genomic neighbors. They cluster around processes that determine whether a chronically inflamed stomach can preserve structure or drifts toward irreversible atrophy.
Cross-Ancestry Data Added One More Locus
Cross-ancestry integration of seronegative severe atrophic gastritis with external chronic gastritis GWAS data identified an additional association at TPTEP1. Even though the main analysis was conducted in Japanese participants, the inclusion of large external datasets broadens the genetic frame and argues against the findings being a cohort-specific artifact. It also suggests that some susceptibility pathways may transcend ancestry, even if the serostatus-specific architecture is most visible in the Japanese cohort analyzed here.
The study’s design strengthens confidence in the overall pattern. Discovery and replication were both substantial, and the use of genotype-by-serostatus interaction, HLA analysis, ABO analysis, genetic correlation methods, and structural equation modeling provided multiple angles on the same question. When different analytic layers converge on the same biology, the signal becomes harder to dismiss as statistical noise.
For bedside care, the implications are straightforward even if the genetics are complex. Patients with atrophic gastritis do not form a single prognostic group. Seropositive and seronegative disease may carry different inherited liabilities, and the seropositive subgroup appears especially entangled with loci already linked to gastric cancer. A patient with atrophic gastritis and evidence of H. pylori-related seropositivity may therefore sit on a more cancer-adjacent pathway than a patient whose disease is shaped primarily by immune-genetic susceptibility. Surveillance, risk communication, and prevention strategies should reflect that heterogeneity rather than treating all atrophic gastritis as interchangeable.
The study closes one gap while opening others. The genetic signals are strong, but they do not yet tell clinicians how to translate serostatus-specific loci into endoscopic intervals, eradication strategies, or biomarker panels. They do, however, establish that the genome recognizes atrophic gastritis as more than a single disease label and that the route from chronic inflammation to carcinoma is biologically shared in measurable ways.